Treatment of hay fever with loratadine--a new non-sedating antihistamine.
The efficacy and safety of loratadine, a new orally active specific H1-receptor blocking antihistamine with poor penetration into the CNS, was evaluated in a double blind comparative study. One hundred and seven hay fever patients, sensitive to birch pollen, were randomized into three parallel groups receiving loratadine 40 mg once daily, clemastine 1 mg twice daily, or placebo during the birch pollen season. Both active treatments showed reduction of symptoms in comparison with placebo, but the results were more pronounced with loratadine treatment, which significantly reduced the overall allergic condition as well as all separate allergic rhino-conjunctivitis symptoms except nasal stuffiness. Compared with placebo the sedation rate was significantly higher with clemastine treatment (P less than 0.05) but not with loratadine. Loratadine was thus concluded to be efficacious in hay fever treatment with a sedation rate not differing from placebo.
Irander
K
K
Department of Otolaryngology, Faculty of Health Sciences, Linköping University, Sweden.
Odkvist
L M
LM
Ohlander
B
B
D002974:Clemastine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003533:Cyproheptadine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006633:Histamine Antagonists / Q000627:therapeutic use*; D006801:Humans; D017336:Loratadine; D008297:Male; D011897:Random Allocation; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D006633:Histamine Antagonists; D003533:Cyproheptadine; D017336:Loratadine; D002974:Clemastine